The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice
Open accessAbstract
An implanted copolymer matrix that incorporates inflammatory cytokines, an immune danger signal, and tumor antigens elicits an immune response network that can eradicate established tumors in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Innate immune recognition of viral infection
Kawai, T., & Akira, S. (2006) · Nature Immunology · doi:10.1038/ni1303 · Cited by 1,899
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869 · cited 1×
“Plasmacytoid DC numbers were closely linked with the generation of type I IFNs, as described in previous studies (10, 21, 38), and these cells helped to support the activation of CD8 DCs and their crosspresentation of tumor antigens to TH1 cells and CTLs (7–9, 13, 27).”
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 3×
“Engineered PLG matrices cause regression of established melanoma Because a high ratio of CD8 T cell effectors to FoxP3 Treg cells has been linked to therapeutic tumor immunity in murine and human systems (33, 35), we tested the activity of PLG vaccines against B16-F10 tumors that had been established for 9 days (inocu…”
BackgroundMethodHodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650
Self-citationCD8 + T‐cell memory in tumor immunology and immunotherapy
Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00391.x · Cited by 511 · cited 5×
“Instead, they may amplify defective CTLs that never become fully functional effectors at the tumor site because of high local concentrations of immunosuppressive cytokines [for example, transforming growth factor–b (TGF-b) and interleukin-10 (IL-10)] and Treg cells, which dampen immune responses (1, 2).”
BackgroundResultInfluential
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Treating metastatic cancer with nanotechnology
Schroeder, A., Heller, D. A., Winslow, M. M., Dahlman, J. E., Pratt, G. W., Langer, R., Jacks, T., & Anderson, D. G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3180 · Cited by 1,159
Advances in Biomaterials for Drug Delivery
Fenton, O. S., Olafson, K. N., Pillai, P. S., Mitchell, M. J., & Langer, R. (2018) · Advanced Materials · doi:10.1002/adma.201705328 · Cited by 855
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
Functional and Biomimetic Materials for Engineering of the Three-Dimensional Cell Microenvironment
Huang, G., Li, F., Zhao, X., Ma, Y., Li, Y., Lin, M., Jin, G., Lu, T. J., Genin, G. M., & Xu, F. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00094 · Cited by 825
Improving cancer immunotherapy through nanotechnology
Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628
Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9537 · Cited by 588
Kim, J., Li, W. A., Choi, Y., Lewin, S. A., Verbeke, C. S., Dranoff, G., & Mooney, D. J. (2015) · Nature Biotechnology · doi:10.1038/nbt.3071 · Cited by 541
Self-citationCancer Nanomedicine: From Drug Delivery to Imaging
Chow, E. K.-H., & Ho, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005872 · Cited by 491
Biomaterial-assisted targeted modulation of immune cells in cancer treatment
Wang, H., & Mooney, D. J. (2018) · Nature Materials · doi:10.1038/s41563-018-0147-9 · Cited by 467
Self-citationBiopolymer implants enhance the efficacy of adoptive T-cell therapy
Stephan, S. B., Taber, A. M., Jileaeva, I., Pegues, E. P., Sentman, C. L., & Stephan, M. T. (2015) · Nature Biotechnology · doi:10.1038/nbt.3104 · Cited by 439
Bioengineering strategies to accelerate stem cell therapeutics
Madl, C. M., Heilshorn, S. C., & Blau, H. M. (2018) · Nature · doi:10.1038/s41586-018-0089-z · Cited by 425
Biomaterials and emerging anticancer therapeutics: engineering the microenvironment
Gu, L., & Mooney, D. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.3 · Cited by 407
Self-citationA melanin-mediated cancer immunotherapy patch
Ye, Y., Wang, C., Zhang, X., Hu, Q., Zhang, Y., Liu, Q., Wen, D., Milligan, J., Bellotti, A., Huang, L., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan5692 · Cited by 381
Beyond antigens and adjuvants: formulating future vaccines
Moyer, T. J., Zmolek, A. C., & Irvine, D. J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci81083 · Cited by 374
Hydrogels and Scaffolds for Immunomodulation
Singh, A., & Peppas, N. A. (2014) · Advanced Materials · doi:10.1002/adma.201402105 · Cited by 355
Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
Park, C. G., Hartl, C. A., Schmid, D., Carmona, E. M., Kim, H.-J., & Goldberg, M. S. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar1916 · Cited by 321
Design, clinical translation and immunological response of biomaterials in regenerative medicine
Sadtler, K., Singh, A., Wolf, M. T., Wang, X., Pardoll, D. M., & Elisseeff, J. H. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.40 · Cited by 319
Latest Advances in Cryogel Technology for Biomedical Applications
Memic, A., Colombani, T., Eggermont, L. J., Rezaeeyazdi, M., Steingold, J., Rogers, Z. J., Navare, K. J., Mohammed, H. S., & Bencherif, S. A. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201800114 · Cited by 310
Phuengkham, H., Ren, L., Shin, I. W., & Lim, Y. T. (2019) · Advanced Materials · doi:10.1002/adma.201803322 · Cited by 306
Macroscale delivery systems for molecular and cellular payloads
Kearney, C. J., & Mooney, D. J. (2013) · Nature Materials · doi:10.1038/nmat3758 · Cited by 301
Self-citationTailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Wang, C., Ye, Y., Hu, Q., Bellotti, A., & Gu, Z. (2017) · Advanced Materials · doi:10.1002/adma.201606036 · Cited by 286
Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy
Goldberg, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.037 · Cited by 278
Antitumour dendritic cell vaccination in a priming and boosting approach
Harari, A., Graciotti, M., Bassani-Sternberg, M., & Kandalaft, L. E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0074-8 · Cited by 271
Enhancing cell therapies from the outside in: Cell surface engineering using synthetic nanomaterials
Stephan, M. T., & Irvine, D. J. (2011) · Nano Today · doi:10.1016/j.nantod.2011.04.001 · Cited by 266
Controlling timing and location in vaccines
Irvine, D. J., Aung, A., & Silva, M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.019 · Cited by 254
Macrophage and dendritic cell phenotypic diversity in the context of biomaterials
Kou, P. M., & Babensee, J. E. (2011) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.32971 · Cited by 190
Biomaterial‐Based Implantable Devices for Cancer Therapy
Chew, S. A., & Danti, S. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201600766 · Cited by 121
Metadata
- Authors
- Ali, O. A., Emerich, D., Dranoff, G., & Mooney, D. J.
- Venue
- Science Translational Medicine
- Published
- 2009-11-25
- Volume
- 1
- Issue
- 8
- Pages
- 8ra19-8ra19
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2070377914
- Cited by
- 246
- References
- 5
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.